Providing actionable clinical insights with
our epigenomics based workflows and know-how
Reporting actionable epigenomic information and analyses from proprietary pipelines and predictive models
Targeting cancers with higher Asian prevalence
Leveraging Asian epigenomics data for novel drug and biomarker discovery
Auristone has successfully completed a US$4 million seed funding round led by Elev8.vc and SEEDS Capital, with a significant follow-on investment from Genedant. This strategic investment will be instrumental in enhancing our capabilities through clinical collaborations, furthering our mission to advance precision medicine through EPI-CALL™.
Auristone is proud to receive the annual T-Up Emerging Awards together with Mr Goh Weixun. This recognizes the exceptional contributions of A*STAR Research Scientists and Engineers (RSEs) to local enterprises such as Auristone, in helping companies achieve significant milestones in their businesses.
Join Auristone and MiRXES for the Memorandum of Understanding (MOU) signing ceremony at the 33rd Annual Scientific Congress of Malaysian Oncological Society (ASCOMOS) at Kuala Lumpur (KL), Malaysia on November 4, 2022 at 5.30 PM.
This webinar discusses the current challenges and advances of immunotherapy using Immune Checkpoint Inhibitors (ICIs) combinations in MSS CRC.
Interested in working with us? Drop us a note below and we’ll get back to you as soon as we can.
enquiry@auristone.com
LaunchPad @ one-north
73 Ayer Rajah Crescent, #02-19 Singapore 139952
